Items where Subject is "RM Therapeutics. Pharmacology"

  • Library of Congress subjects (96929)
  • R Medicine (9332)
  • RM Therapeutics. Pharmacology (227)
    Number of items at this level: 227.
    Article
  • Amisulpride for very late-onset schizophrenia-like psychosis:the ATLAS three-arm RCT. UNSPECIFIED picture_as_pdf
  • Cost-utility analysis of treatment with Olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the Pan-European SOHO study. UNSPECIFIED
  • Publisher correction:model-based therapy planning allows prediction of haemodynamic outcome after aortic valve replacement. UNSPECIFIED
  • A randomised controlled trial of calcium channel blockade (CCB) with amlodipine for the treatment of subcortical ischaemic vascular dementia (AFFECT): study protocol. UNSPECIFIED
  • A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in Saudi Arabia-results from a multi-stakeholder workshop. Al-Omar, Hussain Abdulrahman; Almuhsin, Asma Abdulaziz; Almudaiyan, Lolwa Hamad; Al-Najjar, Amal Hassan; Abu Esba, Laila Carolina; Almodaimegh, Hind; Altawil, Esraa S.; Yousef, Consuela Cheriece; Khan, Mansoor Ahmed; Alyahya, Khalid; Alamre, Jehan; Maraiki, Fatma; Espin, Jaime; Tarricone, Rosanna; Kanavos, Panos picture_as_pdf
  • HTA246 Improving access to innovative therapies for rare bleeding disorders:evidence from high income countries. Alani, A. H.; Eaves, K.; Mills, Mackenzie; Kanavos, P.
  • Researchers on research integrity:a survey of European and American researchers. (2023) Allum, Nick; Reid, Abigail; Bidoglia, Miriam; Gaskell, George; Aubert-Bonn, Noémie; Buljan, Ivan; Fuglsang, Simon; Horbach, Serge; Kavouras, Panagiotis; Marušić, Ana; Mejlgaard, Niels; Pizzolato, Daniel; Roje, Rea; Tijdink, Joeri; Veltri, Giuseppe picture_as_pdf
  • Cost analysis of the treatment of schizophrenia in the UK: a a simulation model comparing olanzapine, risperidone and haloperidol. Almond, Stephen; O'Donnell, Owen
  • A new fuzzy reinforcement learning method for effective chemotherapy. (2023) Alsaadi, Fawaz E.; Yasami, Amirreza; Volos, Christos; Bekiros, Stelios; Jahanshahi, Hadi picture_as_pdf
  • High drug prices are not justified by industry’s spending on research and development. (2023) Angelis, Aris; Polyakov, Roman; Wouters, Olivier J.; Torreele, Els; McKee, Martin picture_as_pdf
  • Early health technology assessment during nonalcoholic steatohepatitis drug development:a two-round, cross-country, multicriteria decision analysis. Angelis, Aris; Thursz, Mark; Ratziu, Vlad; O'Brien, Alistair; Serfaty, Lawrence; Canbay, Ali; Schiefke, Ingolf; Bana e Costa, João C.; Lecomte, Pascal; Kanavos, Panos picture_as_pdf
  • Multiple criteria decision analysis for HTA across four EU member states:piloting the Advance Value Framework. Angelis, Aris; Linch, Mark; Montibeller, Gilberto; Molina Lopez, Maria Teresa; Zawada, Anna; Orzel, Kinga; Arickx, Francis; Espin, Jaime; Kanavos, Panos picture_as_pdf
  • Recalibrating health technology assessment methods for cell and gene therapies. Angelis, Aris; Naci, Huseyin; Hackshaw, Allan picture_as_pdf
  • Study of mirtazapine for agitated behaviours in dementia (SYMBAD):a randomised, double-blind, placebo-controlled trial. Banerjee, Sube; High, Juliet; Stirling, Susan; Shepstone, Lee; Swart, Ann Marie; Telling, Tanya; Henderson, Catherine; Ballard, Clive; Bentham, Peter; Burns, Alistair; Farina, Nicolas; Fox, Chris; Francis, Paul; Howard, Robert; Knapp, Martin; Leroi, Iracema; Livingston, Gill; Nilforooshan, Ramin; Nurock, Shirley; O'Brien, John; Price, Annabel; Thomas, Alan J.; Tabet, Naji picture_as_pdf
  • Use of adherence monitoring in drug contracts tied to outcomes:put patients first. Bartholomew, Theodore; Naci, Huseyin; Robertson, Emma; Schmidt, Harald picture_as_pdf
  • Valuing Alzheimer's disease drugs:a health technology assessment perspective on outcomes. Bauer, Annette; Wittenberg, Raphael; Ly, Amanda; Gustavsson, Anders; Bexelius, Christin; Tochel, Claire; Knapp, Martin; Nelson, Mia; Sudlow, Catherine picture_as_pdf
  • Hemodynamic changes during physiological and pharmacological stress testing in patients with heart failure:a systematic review and meta-analysis. Bingel, Anne; Messroghli, Daniel; Weimar, Andreas; Runte, Kilian; Salcher-Konrad, Maximilian; Kelle, Sebastian; Pieske, Burkert; Berger, Felix; Kuehne, Titus; Goubergrits, Leonid; Fuerstenau, Daniel; Kelm, Marcus picture_as_pdf
  • Availability of new medicines in the US and Germany from 2004 to 2018. Blankart, Katharina; Naci, Huseyin; Chandra, Amitabh picture_as_pdf
  • Applying the win ratio method in clinical trials of orphan drugs:an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease. Boentert, Matthias; Berger, Kenneth I.; Díaz-Manera, Jordi; Dimachkie, Mazen M.; Hamed, Alaa; Riou França, Lionel; Thibault, Nathan; Shukla, Pragya; Ishak, Jack; Caro, J. Jaime picture_as_pdf
  • How to appropriately extrapolate costs and utilities in cost-effectiveness analysis. Bojke, Laura; Manca, Andrea; Asaria, Miqdad; Mahon, Ronan; Ren, Shijie; Palmer, Stephen
  • High rates of long-term HIV RNA re-suppression after virological failure on dolutegravir in the ADVANCE trial. Bosch, B.; Sokhela, S.; Akpomiemie, G.; Chandiwana, N.; Venter, W.D.F.; Simmons, Bryony; McCann, K.; Mirchandani, M.; Hill, A.
  • Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. Brogan, David; Mossialos, Elias
  • Modelling the treated course of schizophrenia: development of a discrete event simulation model. Buskens, Erik; Heeg, Bart M; Knapp, Martin; van Aalast, Gerda; Dries, Pieter J T; de Haan, Lieuwe; van Hout, Ben A
  • Valuing knowledge of the cost and cost-effectiveness of medicines:commentary on... awareness of the cost of psychotropic medication among doctors. Byford, Sarah; Mosweu, Iris
  • Creating contexts for effective home-based care of people living with HIV/AIDS. (2004) Campbell, Catherine; Foulis, C.
  • Rapid diagnostic tests for dengue would reduce hospitalizations, healthcare costs and antibiotic prescriptions in Spain:a cost-effectiveness analysis. (2023) Camprubí-Ferrer, Daniel; Ramponi, Francesco; Balerdi-Sarasola, Leire; Godoy, Ana; Sicuri, Elisa; Muñoz, José picture_as_pdf
  • Combining cash transfers and cognitive behavioral therapy to reduce antisocial behavior in young men:a mediation analysis of a randomized controlled trial in Liberia. (2023) Carpena, Marina Xavier; Paula, Cristiane Silvestre; De Mola, Christian Loret; Hessel, Philipp; Avendano, Mauricio; Evans-Lacko, Sara; Matijasevich, Alicia picture_as_pdf
  • PT7 Reassessment dynamics of orphan drugs in Germany's benefit assessment process. Chavez, D.; Tolkmitt, F.; Mills, M.; Kanavos, P.
  • Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. (2022) Cherla, Avi; Mossialos, Elias; Salcher-Konrad, Maximilian; Kesselheim, Aaron S.; Naci, Huseyin picture_as_pdf
  • The coverage in England of US-approved cancer drugs reply:in reply. Cherla, Avi; Naci, Huseyin; Mossialos, Elias
  • Multi-criteria decision analysis for benefit-risk analysis by national regulatory authorities. (2022) Chisholm, Orin; Sharry, Patrick; Phillips, Lawrence picture_as_pdf
  • Cost-effectiveness of community-based distribution of intermittent preventive treatment of malaria in pregnancy in Madagascar, Mozambique, Nigeria, and the Democratic Republic of Congo. (2023) Cirera, Laia; Sacoor, Charfudin; Meremikwu, Martin; Ranaivo, Louise; Manun'ebo, Manu F.; Pons-Duran, Clara; Arikpo, Dachi; Ramirez, Maximo; Ramponi, Francesco; Figueroa-Romero, Antia; Gonzalez, Raquel; Maly, Christina; Roman, Elaine; Sicuri, Elisa; Pagnoni, Franco; Menéndez, Clara picture_as_pdf
  • HTA18 First to launch, first to falter?:an investigation into the clinical benefits and HTA outcomes for first-in-class drugs. Civitelli, D.; Politopoulou, K.; Mills, Mackenzie; Kanavos, P.
  • Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias:the GREAT RCT. Clare, Linda; Kudlicka, Aleksandra; Oyebode, Jan R.; Jones, Roy W.; Bayer, Antony; Leroi, Iracema; Kopelman, Michael; James, Ian A.; Culverwell, Alison; Pool, Jackie; Brand, Andrew; Henderson, Catherine; Hoare, Zoe; Knapp, Martin; Morgan-Trimmer, Sarah; Burns, Alistair; Corbett, Anne; Whitaker, Rhiannon; Woods, Bob
  • From here to I.A.P.T? (improving access to psychological therapies), preview for a new deal for dynamic psychotherapies:the psychoanalyst as street-level bureaucrat. Clarke, Jeremy picture_as_pdf
  • A new deal for dynamic psychotherapies:the psychoanalyst as street‐level bureaucrat. Clarke, Jeremy picture_as_pdf
  • Pharmacy interventions on COVID-19 in Europe:mapping current practices and a scoping review. (2022) Costa, Suzete; Romão, Mariana; Mendes, Maria; Horta, Maria Rute; Rodrigues, António Teixeira; Carneiro, António Vaz; Martins, Ana Paula; Mallarini, Erika; Naci, Huseyin; Babar, Zaheer Ud Din picture_as_pdf
  • Pharmaceutical policy reform in Spain. Costa-Font, Joan; McDaid, David
  • Cost-utility of attachment-based compassion therapy (ABCT) and Mindfulness-Based Stress Reduction (MBSR) in the management of depressive, anxious, and adjustment disorders in mental health settings:economic evaluation alongside a randomized controlled trial. D'Amico, Francesco; Navarrete, Jaime; Montero-Marín, Jesús; Cardeñosa-Valera, Eugenia; Navarro-Gil, Mayte; Pérez-Aranda, Adrián; López-del-Hoyo, Yolanda; Collado-Navarro, Carlos; García-Campayo, Javier; Luciano, Juan V. picture_as_pdf
  • Communication of anticancer drug benefits and related uncertainties to patients and clinicians:document analysis of regulated information on prescription drugs in Europe. (2023) Davis, Courtney; Wagner, Anita K.; Salcher-Konrad, Maximilian; Scowcroft, Henry; Mintzes, Barbara; Pokorny, Adrian M J; Lew, Jianhui; Naci, Huseyin picture_as_pdf
  • Allergen immunotherapy for allergic asthma:A systematic review and meta-analysis. Dhami, S.; Kakourou, A.; Asamoah, F.; Agache, I.; Lau, S.; Jutel, M.; Muraro, A.; Roberts, G.; Akdis, C. A.; Bonini, M.; Cavkaytar, O.; Flood, B.; Gajdanowicz, P.; Izuhara, K.; Kalayci; Mosges, R.; Palomares, O.; Pfaar, O.; Smolinska, S.; Sokolowska, M.; Asaria, M.; Netuveli, G.; Zaman, H.; Akhlaq, A.; Sheikh, A.
  • Allergen immunotherapy for insect venom allergy:a systematic review and meta-analysis. Dhami, S.; Zaman, H.; Varga, E. M.; Sturm, G. J.; Muraro, A.; Akdis, C. A.; Antolín-Amérigo, D.; Bilò, M. B.; Bokanovic, D.; Calderon, M. A.; Cichocka-Jarosz, E.; Oude Elberink, J. N.G.; Gawlik, R.; Jakob, T.; Kosnik, M.; Lange, J.; Mingomataj, E.; Mitsias, D. I.; Mosbech, H.; Ollert, M.; Pfaar, O.; Pitsios, C.; Pravettoni, V.; Roberts, G.; Ruëff, F.; Sin, B. A.; Asaria, M.; Netuveli, G.; Sheikh, A.
  • Moving from traditional to more advanced treatments in stroke care is cost-effective:a case study from Greece. Dimitriadis, Konstantinos; Kyriopoulos, Ilias; Tsivgoulis, Georgios; Vemmos, Konstantinos; Kunz, Wolfgang G.; Mossialos, Elias
  • Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Duggan, Andy; Warner, Juliet; Knapp, Martin; Kerwin, Robert
  • Health technology assessment criteria as drivers of coverage with managed entry agreements:a case study of cancer medicines in four countries. (2022) Efthymiadou, Olina picture_as_pdf
  • Impact of Managed Entry Agreements on availability of and timely access to medicines:an ex-post evaluation of agreements implemented for oncology therapies in four countries. (2022) Efthymiadou, Olina; Kanavos, Panos picture_as_pdf
  • Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021. (2023) Feldman, William B.; Tu, S. Sean; Alhiary, Rasha; Kesselheim, Aaron S.; Wouters, Olivier J. picture_as_pdf
  • Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study). Feliu-Soler, Albert; Borràs, Xavier; Peñarrubia-María, María T.; Rozadilla-Sacanell, Antoni; D’Amico, Francesco; Moss-Morris, Rona; Howard, Matthew A.; Fayed, Nicolás; Soriano-Mas, Carles; Puebla-Guedea, Marta; Serrano-Blanco, Antoni; Pérez-Aranda, Adrián; Tuccillo, Raffaele; Luciano, Juan V.
  • Evaluation of the cost effectiveness of Escitalopram versus Venlafaxine XR in major depressive disorder. Fernández, José-Luis; Montgomery, Stuart; Francois, Clément
  • Perspectives in the study of the political economy of COVID-19 vaccine regulation. (2022) Fonseca, Elize M.da; Jarman, Holly; King, Elizabeth J.; Greer, Scott L. picture_as_pdf
  • Market access for medicines treating rare diseases:association between specialised processes for orphan medicines and funding recommendations. (2022) Fontrier, Anna-Maria picture_as_pdf
  • Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community. (2024) Forlano, Roberta; Stanic, Tijana; Jayawardana, Sahan; Mullish, Benjamin H.; Yee, Michael; Mossialos, Elias; Goldin, Robert D.; Petta, Salvatore; Tsochatzis, Emmanouil; Thursz, Mark R.; Manousou, Pinelopi picture_as_pdf
  • Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. Fu, Mengyuan; Naci, Huseyin; Booth, Christopher M.; Gyawali, Bishal; Cosgrove, Austin; Toh, Sengwee; Xu, Ziyue; Guan, Xiaodong; Ross-Degnan, Dennis; Wagner, Anita K.
  • Study protocol for a three-arm randomized controlled trial investigating the effectiveness, cost-utility, and physiological effects of a fully self-guided digital Acceptance and Commitment Therapy for Spanish patients with fibromyalgia. Gallego, Ana; Serrat, Mayte; Royuela-Colomer, Estíbaliz; Sanabria-Mazo, Juan P.; Borràs, Xavier; Esteve, Montserrat; Grasa, Mar; Rosa, Araceli; Rozadilla-Sacanell, Antoni; Almirall, Miriam; D'Amico, Francesco; Dai, Yifei; Rosenbluth, Michael J.; McCracken, Lance M.; Navarrete, Jaime; Feliu-Soler, Albert; Luciano, Juan V. picture_as_pdf
  • Trusting the results of model-based economic analyses: is there a pragmatic validation solution? Ghabri, Salah; Stevenson, Matt; Möller, Jörgen; Caro, J. Jaime picture_as_pdf
  • MSR1 Estimating lifetime benefits of optimizing secondary preventive treatment for atherosclerotic cardiovascular disease. Gill, Jennifer L; Miracolo, Aurelio; Politopoulou, Konstantina; Jayawardana, Sahan; Apostolou, Efstratios A.; Carter, Alex; Kanavos, Panos
  • Projections of future burden of pharmacologically treated type 2 diabetes and associated life expectancies by income in Finland:a multi-state modeling study. Guzman-Castillo, Maria; Korhonen, Kaarina; Murphy, Michael; Martikainen, Pekka picture_as_pdf
  • Challenges in diabetes mellitus type 2 management in Nepal: a literature review. Gyawali, Bishal; Ferrario, Alessandra; van Teijlingen, Edwin; Kallestrup, Per
  • Patients’ experiences treated with open-label placebo versus double-blind placebo:a mixed methods qualitative study. (2022) Haas, Julia W.; Ongaro, Giulio; Jacobson, Eric; Conboy, Lisa A.; Nee, Judy; Iturrino, Johanna; Rangan, Vikram; Lembo, Anthony; Kaptchuk, Ted J.; Ballou, Sarah picture_as_pdf
  • Physician antipsychotic overprescribing letters and cognitive, behavioral, and physical health outcomes among people with dementia:a secondary analysis of a randomized clinical trial. (2024) Harnisch, Michelle; Barnett, Michael l.; Coussens, Stephen; Thomas, Kali s.; Olfson, Mark; Berhane, Kiros; Sacarny, Adam picture_as_pdf
  • Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor público. Helfer, Ana Paula; Camargo, Aline Lins; Tavares, Noemia Urruth Leão; Kanavos, Panos; Bertoldi, Andréa Dâmaso
  • Cost-effectiveness of an online intervention for caregivers of people living with dementia. (2022) Henderson, Catherine; Knapp, Martin; Fossey, Jane; Frangou, Elena; Ballard, Clive picture_as_pdf
  • Cost-effectiveness of mirtazapine for agitated behaviors in dementia:findings from a randomized controlled trial. (2022) Henderson, Catherine; Knapp, Martin; Stirling, Susan; Shepstone, Lee; High, Juliet; Ballard, Clive; Bentham, Peter; Burns, Alistair; Farina, Nicolas; Fox, Chris; Fountain, Julia; Francis, Paul; Howard, Robert; Leroi, Iracema; Livingston, Gill; Nilforooshan, Ramin; Nurock, Shirley; O’brien, John T.; Price, Annabel; Swart, Ann Marie; Tabet, Naji; Telling, Tanya; Thomas, Alan J.; Banerjee, Sube picture_as_pdf
  • Net prices of new antiobesity medications. Hernandez, Inmaculada; Sullivan, Sean D.
  • Price benchmarks of drugs selected for medicare price negotiation and their therapeutic alternatives. (2024) Hernandez, Inmaculada; Cousin, Emma M.; Wouters, Olivier J.; Gabriel, Nico; Cameron, Teresa; Sullivan, Sean D. picture_as_pdf
  • Low CD4 counts predict excessive weight gains during first-line treatment for HIV. Hill, Andrew; Tovar sanchez, Tamara; Delaporte, Eric; Sokhela, Simiso; Simmons, Bryony; Kouanfack, Charles; Mccann, Kaitlyn; Levi, Jacob; Fairhead, Cassandra; Venter, Francois picture_as_pdf
  • A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. Hong, Jihyung; Dilla, Tatiana; Arellano, Jorge
  • Beliefs and practices about antiretroviral medication: a study of poor urban Kenyans living with HIV/AIDS. Izugbara, Chimaraoke O.; Wekesa, Eliud
  • Global consumption patterns of combination hypertension medication:an analysis of pharmaceutical sales data from 2010–2021. Jayawardana, Sahan; Campbell, Allen; Aitken, Murray; Andersson, Charlotte E.; Mehra, Mandeep R.; Mossialos, Elias picture_as_pdf
  • Global consumption of prescription opioid analgesics between 2009-2019:a country-level observational study. (2021) Jayawardana, Sahan; Forman, Rebecca; Johnston-Webber, Charlotte; Campbell, Allen; Berterame, Stefano; de Joncheere, Cees; Aitken, Murray; Mossialos, Elias picture_as_pdf
  • Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland:a retrospective, comparative analysis. (2024) Jenei, Kristina; Gentilini, Arianna; Haslam, Alyson; Prasad, Vinay picture_as_pdf
  • Characteristics of clinician input in Canadian funding decisions for cancer drugs:a cross-sectional study based on CADTH reimbursement recommendations. Jenei, Kristina; Meyers, Daniel picture_as_pdf
  • The price effects of biosimilars in the United States. Jofre-Bonet, Mireia; McGuire, Alistair; Dayer, Victoria; Roth, Joshua A; Sullivan, Sean D
  • The impact of generic entry of pharmaceuticals in Australia. Jones, Arun M.; Serra-Sastre, Victoria; Kim, Hansoo picture_as_pdf
  • Sodium nitrite–mediated cardioprotection in primary percutaneous coronary intervention for ST-Segment Elevation Myocardial Infarction:a cost-effectiveness analysis. Jones, Daniel A.; Whittaker, Peter; Rathod, Krishnaraj S.; Richards, Amy J.; Andiapen, Mervyn; Antoniou, Sotiris; Mathur, Anthony; Ahluwalia, Amrita
  • DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease: a multicentre RCT. Jones, Rob; Sheehan, Bart; Phillips, Patrick; Knapp, Martin
  • Droplet microfluidics platform for highly sensitive and quantitative detection of malaria-causing plasmodium parasites based on enzyme activity measurement. Juul, Sissel; Nielsen, Christine J. F.; Labouriau, Rodrigo; Roy, Amit; Tesauro, Cinzia; Jensen, Pia W.; Harmsen, Charlotte; Kristoffersen, Emil L.; Chiu, Ya-Ling; Frøhlich, Rikke; Fiorani, Paola; Cox-Singh, Janet; Tordrup, David; Koch, Jørn; Bienvenu, Anne-Lise; Desideri, Alessandro; Picot, Stephane; Petersen, Eskild; Leong, Kam W.; Ho, Yi-Ping; Stougaard, Magnus; Knudsen, Birgitta R.
  • Financing pharmaceuticals in transition. Kanavos, Panos
  • Competition in off-patent drug markets: issues, regulation and evidence. Kanavos, Panos; Costa-i-Font, Joan; Seeley, Elizabeth
  • Drugs US: are prices too high?: measuring international pharmaceutical price differences. Kanavos, Panos; Vandoros, Sotiris
  • App-based food-specific inhibitory control training as an adjunct to treatment as usual in binge-type eating disorders:a feasibility trial. (2022) Keeler, Johanna Louise; Chami, Rayane; Cardi, Valentina; Hodsoll, John; Bonin, Eva; MacDonald, Pamela; Treasure, Janet; Lawrence, Natalia picture_as_pdf
  • Comparative effectiveness and safety of concomitant treatment with Chuna Manual Therapy and usual care for whiplash injuries:a multicenter randomized controlled trial. Kim, Byung-Jun; Park, A-La; Hwang, Man-Suk; Heo, In; Park, Sun-Young; Cho, Jae-Heung; Kim, Koh-Woon; Lee, Jun-Hwan; Ha, In-Hyuk; Park, Kyoung-Sun; Hwang, Eui-Hyoung; Shin, Byung-Cheul picture_as_pdf
  • Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study. King, Derek; Knapp, Martin; Thomas, P.; Razzouk, D.; Loze, J.-Y.; Kan, H.J.; van Baardewijk, M.
  • Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Knapp, Martin; King, Derek; Pugner, Klaus; Lapuerta, Pablo
  • Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER. Knapp, Martin; Locklear, Julie; Jarbrink, Krister
  • Recovery and economics. Knapp, Martin; McDaid, David; Park, A-La
  • Underuse of medication for circulatory disorders among unmarried women and men in Norway? Kravdal, Øystein; Grundy, Emily
  • Managing the introduction of new and high-cost drugs in challenging times: the experience of Hungary and Poland. Kwong, Danica; Ferrario, Alessandra; Adamski, Jajub; Inotai, Andras; Kalo, Zoltan
  • The effect of prescription drug insurance on the incidence of potentially inappropriate prescribing:evidence from Medicare Part D. Lee, Donghoon; Kim, SangJune; Dugan, Jerome A. picture_as_pdf
  • The 30-billion-dollar distribution markups and taxes of pharmaceuticals in Latin American countries:impact, options, and trade-offs. Leon, Giovanny; Gonzalez-Pier, Eduardo; Kanavos, Panos; Ruiz de Castilla, Eva Maria; Machinicki, Gerardo picture_as_pdf
  • New deviancy theory and the healthcare system's role in creating, labeling, and facilitating unauthorized prescription drug “abuse”. Levin, David; Shiner, Michael
  • Optimisation-based modelling for explainable lead discovery in malaria. Li, Yutong; Cardoso-Silva, Jonathan; Kelly, John M.; Delves, Michael J.; Furnham, Nicholas; Papageorgiou, Lazaros G.; Tsoka, Sophia picture_as_pdf
  • Correction to:which costs matter? Costs included in economic evaluation and their impact on decision uncertainty for stable coronary artery disease. Lomas, James; Asaria, Miqdad; Bojke, Laura; Gale, Chris P.; Richardson, Gerry; Walker, Simon picture_as_pdf
  • Wat kost onderzoek en ontwikkeling van een medicijn? Een oproep tot meer transparantie. Luyten, Jeroen; McKee, Martin; Wouters, Olivier J. picture_as_pdf
  • From vision to reality:the EU's pharmaceutical reforms and the path to improved access. Main, Caitlin; Schafer, Cathrin; Kanavos, Panos picture_as_pdf
  • Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Malmström, Rickard E.; Godman, Brian B.; Diogene, Eduard; Baumgärtel, Christoph; Bennie, Marion; Bishop, Iain; Brzezinska, Anna; Bucsics, Anna; Campbell, Stephen; Ferrario, Alessandra; Finlayson, Alexander E.; Fürst, Jurij; Garuoliene, Kristina; Gomes, Miguel; Gutiérrez-Ibarluzea, Iñaki; Haycox, Alan; Hviding, Krystyna; Herholz, Harald; Hoffmann, Mikael; Jan, Saira; Jones, Jan; Joppi, Roberta; Kalaba, Marija; Kvalheim, Christina; Laius, Ott; Langner, Irene; Lonsdale, Julie; Lööv, Sven-Äke; Malinowska, Kamila; McCullagh, Laura; Paterson, Ken; Markovic-Pekovic, Vanda; Martin, Andrew; Piessnegger, Jutta; Selke, Gisbert; Sermet, Catherine; Simoens, Steven; Tulunay, Cankat; Tomek, Dominik; Vončina, Luka; Vlahovic-Palcevski, Vera; Wale, Janet; Wilcock, Michael; Wladysiuk, Magdalena; Woerkom, Menno van; Zara, Corrine; Gustafsson, Lars L.
  • A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients. Manfrin, Andrea; Tinelli, Michela; Thomas, Trudy; Krska, Janet
  • Improving access to medicines:lessons from 10 years of drug reforms in China, 2009-2020. (2022) Mao, Wenhui; Jiang, Hongli; Mossialos, Elias; Chen, Wen picture_as_pdf
  • Are large prospective trials on antidepressants in mental disorders seeding trials?:a descriptive study of trials registered on ClinicalTrials.gov. Martineau, Samuel; Cristea, Ioana-Alina; Chevance, Astrid; Fanelli, Daniele; Naudet, Florian picture_as_pdf
  • Brazil’s fight against Hepatitis C:universalism, local production, and patents. Massard da Fonseca, Elize; Shadlen, Kenneth C.; Inácio Bastos, Francisco picture_as_pdf
  • IMPACT smoking cessation support for people with severe mental illness in South Asia (IMPACT 4S):a protocol for a randomised controlled feasibility trial of a combined behavioural and pharmacological support intervention. (2023) Mazumdar, Papiya; Zavala, Gerardo; Aslam, Faiza; Muliyala, Krishna Prasad; Chaturvedi, Santosh Kumar; Kandasamy, Arun; Nizami, Asad; Ul Haq, Baha; Kellar, Ian; Jackson, Cath; Thomson, Heather; McDaid, David; Siddiqi, Kamran; Hewitt, Catherine; Siddiqi, Najma; Gilbody, Simon; Murthy, Pratima; Dadirai Mdege, Noreen picture_as_pdf
  • Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. McCrone, Paul R.; Chisholm, Daniel; Knapp, Martin; Hughes, Richard; Comi, Giancarlo; Dalakas, Marinos C.; Illa, Isabel; Kilindireas, Costas; Nobile-Orazio, Eduardo; Swan, Anthony Victor; Van den Bergh, Peter; Willison, Hugh J.
  • Cost-effectiveness of individual versus group psychotherapy for sexually abused girls. McCrone, Paul R.; Weeramanthri, Tara; Knapp, Martin R.J.; Rushton, Alan; Trowell, Judith; Miles, Gillian; Kolvin, Israel
  • The European value-pricing game. McGuire, Alistair
  • Overview of the Arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. McGuire, Alistair; Burke, T.; Goldstein, J.; Maniadakis, N.; Pettitt, D.
  • 640P Tumor response rate for hematologic and solid cancer drugs with FDA approval supported by single-arm trials. Michaeli, D. T.; Michaeli, J. C.; Mossialos, E.; Albers, S.; Michaeli, C. T.
  • Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. (2022) Michaeli, Daniel Tobias; Mills, Mackenzie; Michaeli, Thomas; Miracolo, Aurelio; Kanavos, Panos picture_as_pdf
  • Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination in South Africa. (2022) Michaeli, Daniel Tobias; Stoycheva, Sophia; Marcus, Simon Mashudu; Zhang, Wenjia; Michaeli, Julia Caroline; Michaeli, Thomas picture_as_pdf
  • Healthcare payer perspectives on the assessment and pricing of oncology multi-indication products:evidence from nine OECD countries. (2023) Mills, Mackenzie; Kanavos, Panos picture_as_pdf
  • HTA barriers for conditional approval drugs. (2023) Mills, Mackenzie picture_as_pdf
  • The increasing need to harmonize evidence demands of regulators, payers, and health technology assessment bodies in Europe – opportunities and challenges. Naci, Huseyin
  • Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16:cross-sectional analysis. Naci, Huseyin; Davis, Courtney; Savović, Jelena; Higgins, Julian P. T.; Sterne, Jonathan; Gyawali, Bishal; Romo Sandoval, Xochitl Citlalli; Handley, Nicola; Booth, Christopher M picture_as_pdf
  • Characteristics of prior authorization policies for new drugs in Medicare Part D. (2023) Naci, Huseyin; Forrest, Robin; Zhai, Mike; Stofesky, Amanda R.; Kesselheim, Aaron S. picture_as_pdf
  • Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs. Naci, Huseyin; Guan, Xiaodong; Woloshin, Steven; Xu, Ziyue; Wagner, Anita K. picture_as_pdf
  • Producing and using timely comparative evidence on drugs:lessons from clinical trials for covid-19. Naci, Huseyin; Kesselheim, Aaron S.; Rttingen, John Arne; Salanti, Georgia; Vandvik, Per O.; Cipriani, Andrea description
  • Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20:a retrospective analysis. Naci, Huseyin; Murphy, Peter; Woods, Beth; Lomas, James; Wei, Jinru; Papanicolas, Irene picture_as_pdf
  • How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 RCTs assessing exercise and medication effects on systolic blood pressure. (2018) Naci, Huseyin; Salcher-Konrad, Maximilian; Dias, Sofia; Blum, Manuel R.; Sahoo, Samali Anova; Nunan, David; Ioannidis, John P. A. picture_as_pdf
  • Impact of predictive medicine on therapeutic decision making:a randomized controlled trial in congenital heart disease. Naci, Huseyin; Salcher-Konrad, Maximilian; Mcguire, Alistair; Berger, Felix; Kuehne, Titus; Goubergrits, Leonid; Muthurangu, Vivek; Wilson, Ben; Kelm, Marcus picture_as_pdf
  • Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs. Naci, Huseyin; van Valkenhoef, G.; Higgins, J. P. T.; Fleurence, R.; Ades, A. E.
  • Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB):protocol for a randomised controlled trial. (2024) Namale, Phiona E.; Boloko, Linda; Vermeulen, Marcia; Haigh, Kate A.; Bagula, Fortuna; Maseko, Alexis; Sossen, Bianca; Lee-Jones, Scott; Msomi, Yoliswa; McIlleron, Helen; Mnguni, Ayanda Trevor; Crede, Thomas; Szymanski, Patryk; Naude, Jonathan; Ebrahim, Sakeena; Vallie, Yakoob; Moosa, Muhammed Shiraz; Bandeker, Ismail; Hoosain, Shakeel; Nicol, Mark P.; Samodien, Nazlee; Centner, Chad; Dowling, Wentzel; Denti, Paolo; Gumedze, Freedom; Little, Francesca; Parker, Arifa; Price, Brendon; Schietekat, Denzil; Simmons, Bryony; Hill, Andrew; Wilkinson, Robert J.; Oliphant, Ida; Hlungulu, Siphokazi; Apolisi, Ivy; Toleni, Monica; Asare, Zimkhitha; Mpalali, Mkanyiseli Kenneth; Boshoff, Erica; Prinsloo, Denise; Lakay, Francisco; Bekiswa, Abulele; Jackson, Amanda; Barnes, Ashleigh; Johnson, Ryan; Wasserman, Sean; Maartens, Gary; Barr, David; Schutz, Charlotte; Meintjes, Graeme picture_as_pdf
  • Generic cardiology drug prices:the potential benefits of the Marc Cuban cost plus drug company model. Narendrula, Aparna; Lang, Jacob; Mossialos, Elias picture_as_pdf
  • Snake oil or super drug:how have regulators and payers perceived new medicines that target asymptomatic conditions? Needham, Brian Richard picture_as_pdf
  • European Medicines Agency’s Priority Medicines scheme at 2 years:an evaluation of clinical studies supporting eligible drugs. Neez, Emilie Marie Celine Anne; Hwang, Thomas; Sahoo, Samali Anova; Naci, Huseyin picture_as_pdf
  • COVID-19 vaccination personas in Syria:evidence from a cross-sectional survey. Nikoloski, Zlatko; Aliyev, Elnur; Bain, Robert E.S.; Menchini, Leonardo; Hegazi, Sahar; Zalkha, Mai; Mouawad, Shaza; Kapil, Neha; Gillespie, Amaya M. picture_as_pdf
  • COVID-19 vaccination personas in Yemen:insights from three rounds of a cross-sectional survey. Nikoloski, Zlatko; Chimenya, Dennis; Alshehari, Abdullah; Hassan, Hauwa; Bain, Robert; Menchini, Leonardo; Gillespie, Amaya picture_as_pdf
  • Cost-effectiveness analysis of filgotinib versus tofacitinib as first-line treatments for rheumatoid arthritis in Greece. Nomikos, N.; Naoum, P.; Athanasakis, K.; Kyriopoulos, I
  • EE477 A budget impact analysis of introducing filgotinib for the treatment of rheumatoid arthritis in Greece. Nomikos, N.; Naoum, P.; Athanasakis, K.; Kyriopoulos, I
  • EE478 A budget impact analysis of introducing filgotinib as a first-line treatment for moderate to severe ulcerative colitis in Greece. Nomikos, N.; Naoum, P.; Athanasakis, K.; Kyriopoulos, I
  • Cost-effectiveness analysis of filgotinib as a first-line treatment for biologic-naive patients with Ulcerative Colitis in Greece. Nomikos, N.; Naoum, P.; Athanasakis, Kostas; Kyriopoulos, I
  • So near yet so far:why won't the UK prescribe medical cannabis? (2020) Nutt, David; Bazire, Steve; Phillips, Lawrence D.; Schlag, Anne Katrin picture_as_pdf
  • A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products. (2022) Nutt, David J.; Phillips, Lawrence D.; Barnes, Michael; Brander, Brigitta; Curran, H. Valerie; Fayaz, Alan; Finn, David P.; Horsted, Tina; Moltke, Julie; Sakal, Chloe; Sharon, Haggai; O’Sullivan, Saoirse; Williams, Tim; Zorn, Gregor; Schlag, Anne Katrin picture_as_pdf
  • As if gender mattered: reconsidering the implications of ‘intoxicating stories’. O'Neill, Rachel
  • Does industry really develop less medicine with clinical benefit?—Reply. Osipenko, Leeza
  • Understanding decisions about antibiotic prescribing in ICU:an application of the Necessity Concerns Framework. (2022) Pandolfo, Alyssa M.; Horne, Robert; Jani, Yogini; Reader, Tom W.; Bidad, Natalie; Brealey, David; Enne, Virve I.; Livermore, David M.; Gant, Vanya; Brett, Stephen J. picture_as_pdf
  • The use of complementary and alternative medicine by adults with allergies:a Czech national representative survey. (2021) Pokladnikova, Jitka; Park, A-La; Draessler, Jan; Lukacisinova, Anna; Krcmova, Irena picture_as_pdf
  • HTA255 First-in-class drugs in HTA:blunder or bliss? Politopoulou, Konstantina; Mills, Mackenzie; Kanavos, Panos
  • What should we do about student use of cognitive enhancers?: an analysis of current evidence. Ragan, C. Ian; Bard, Imre; Singh, Ilina
  • Sensory integration therapy versus usual care for sensory processing difficulties in autism spectrum disorder in children:study protocol for a pragmatic randomised controlled trial. Randell, Elizabeth; McNamara, Rachel; Delport, Sue; Busse, Monica; Hastings, Richard P.; Gillespie, David; Williams-Thomas, Rhys; Brookes-Howell, Lucy; Romeo, Renee; Boadu, Janet; Ahuja, Alka S.; McKigney, Anne Marie; Knapp, Martin; Smith, Kathryn; Thornton, Jacqui; Warren, Gemma
  • A new approach to formulating and appraising drug policy: a multi-criterion decision analysis applied to alcohol and cannabis regulation. Rogeberg, Ole; Bergsvik, Daniel; Phillips, Lawrence D.; Amsterdam, Jan van; Eastwood, Niamh; Henderson, Graeme; Lynskey, Michael; Measham, Fiona; Ponton, Rhys; Rolles, Steve; Schlag, Anne Katrin; Taylor, Polly; Nutt, David
  • Defining a framework for sustainable global biosimilars markets using findings from a targeted literature review. (2025) Roth, Joshua A; Dayer, Victoria W.; Jofre-Bonet, Mireia; McGuire, Alistair; Sullivan, Sean D.
  • Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Sado, Mitsuhiro; Knapp, Martin; Yamauchi, Keita; Fujisawa, Daisuke; So, Mirai; Nakagawa, Atsuo; Kikuchi, Toshiaki; Ono, Yutaka
  • Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. Salas-Vega, Sebastian; Iliopoulos, Othon; Mossialos, Elias
  • Treatment effects in randomized and nonrandomized studies of pharmacological interventions:a meta-analysis. Salcher-Konrad, Maximilian; Nguyen, Mary; Savović, Jelena; Higgins, Julian P. T.; Naci, Huseyin picture_as_pdf
  • Prescriber commitment posters to increase prudent antibiotic prescribing in English general practice:a cluster randomized controlled trial. Sallis, Anna; Bondaronek, Paulina; Sanders, Jet G.; Yu, Ly Mee; Harris, Victoria; Vlaev, Ivo; Sanders, Michael; Tonkin-Crine, Sarah; Chadborn, Tim picture_as_pdf
  • Economic evaluation of videoconference group Acceptance and Commitment Therapy and Behavioral Activation Therapy for depression versus usual care among adults with chronic low back pain plus comorbid depressive symptoms. Sanabria-Mazo, Juan P.; D'Amico, Francesco; Cardeñosa, Eugenia; Ferrer-Forés, Monserrat; Edo, Sílvia; Borràs, Xavier; McCracken, Lance M.; Feliu-Soler, Albert; Sanz, Antoni; Luciano, Juan V. picture_as_pdf
  • The value of real world evidence:the case of medical cannabis. (2022) Schlag, Anne Katrin; Zafar, Rayyan R.; Lynskey, Michael T.; Athanasiou-Fragkouli, Alkyoni; Phillips, Lawrence D.; Nutt, David J. picture_as_pdf
  • Does NICE influence the adoption and uptake of generics in the UK? Serra-Sastre, Victoria; Bianchi, Simona; Mestre-Ferrandiz, Jorge; O’Neill, Phill picture_as_pdf
  • Accelerating pooled licensing of medicines to enhance global production and equitable access. (2022) Shadlen, Kenneth C.
  • Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe:lessons for the accelerated approval pathway. (2024) Shahzad, Mahnum; Naci, Huseyin; Esselen, Katharine M.; Dottino, Joseph A.; Wagner, Anita K. picture_as_pdf
  • Beyond polemics: science and ethics of ADHD. Singh, Ilina
  • Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. Sokhela, Simiso; Bosch, Bronwyn; Hill, Andrew; Simmons, Bryony; Woods, Joana; Johnstone, Hilary; Akpomiemie, Godspower; Ellis, Leah; Owen, Andrew; Casas, Carmen Perez; Venter, Willem Daniel Francois picture_as_pdf
  • Evidence of comparative efficacy should have a formal role in European drug approvals. Sorenson, Corinna; Naci, Huseyin; Cylus, Jonathan; Mossialos, Elias
  • The cognitive footprint of medication:a review of cognitive assessments in clinical trials. Stoner, Charlotte R; Knapp, Martin; Luyten, Jeroen; Kung, Claryn; Richards, Marcus; Rossor, Martin picture_as_pdf
  • Health effects associated with Kratom (Mitragyna speciosa) and polysubstance use:a narrative review. (2022) Striley, Catherine W.; Hoeflich, Carolin C.; Viegas, Andrew T.; Berkowitz, Lindsey A.; Matthews, Emily G.; Akin, Leyla P.; Iheanyi-Okeahialam, Chidinma; Mansoor, Urmeen; McCurdy, Christopher R. picture_as_pdf
  • Medicare drug price negotiation in the United States:implications and unanswered questions. (2023) Sullivan, Sean D.
  • Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States. Sullivan, Sean D.; Chaturvedi, Shruti; Gautam, Preety; Arnaud, Alix
  • Has the Centers for Medicare & Medicaid Services implicitly adopted a value framework for Medicare drug price negotiations? Sullivan, Sean D.; Hernandez, Inmaculada; Ramsey, Scott D.; Neumann, Peter J.
  • Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study. Surguladze, Simon; Patel, Anita; Kerwin, Robert W; Knapp, Martin; Travis, Michael J
  • A systematic review of nudge interventions to optimize medication prescribing. Talat, Usman; Schmidtke, Kelly Ann; Khanal, Saval; Chan, Amy; Turner, Alice; Horne, Robert; Chadborn, Tim; Gold, Natalie; Sallis, Anna; Vlaev, Ivo picture_as_pdf
  • Relative impact of diagnosis and clinical stage on response to electroconvulsive therapy:a retrospective cohort. Tedeschi, Eduardo; Hoffmann, Mauricio Scopel; Magalhaes, Pedro V. S. picture_as_pdf
  • Moderating effects of diagnosis and gender on the influence of age on electroconvulsive therapy outcome. Tedeschi, Eduardo; Hoffmann, Mauricio S.; Magalhães, Pedro V.S. picture_as_pdf
  • Quantifying preference in drug benefit-risk decisions. Tervonen, Tommi; Angelis, Aris; Hockley, Kimberley; Pignatti, Francesco; Phillips, Lawrence D. picture_as_pdf
  • Quantitative bias analysis for external control arms using real-world data in clinical trials:a primer for clinical researchers. (2024) Thorlund, Kristian; Duffield, Stephen; Popat, Sanjay; Ramagopalan, Sreeram; Gupta, Alind; Hsu, Grace; Arora, Paul; Subbiah, Vivek picture_as_pdf
  • Menopausa e terapia ormonale sostitutiva: qualità di vita e farmacoeconomia. Tinelli, Michela
  • Progetto pilota per la rilevazione delle prescrizioni farmaceutiche in Farmacia. Tinelli, Michela
  • Development, validation and application of a patient satisfaction scale for a community pharmacy medicines-management service. Tinelli, Michela; Blenkinsopp, Alison; Bond, Christine
  • Economic evaluation of anti-epileptic medicines for autistic children with epilepsy. (2023) Tinelli, Michela; Roddy, Áine; Knapp, Martin; Arango, Celso; Mendez, Maria Andreina; Henderson, Catherine; Murphy, Declan; Canitano, Roberto; Oakley, Bethany; Quoidbach, Vinciane picture_as_pdf
  • Clinical, ethical, and socioeconomic considerations for prescription drug use during pregnancy in women suffering from chronic diseases. Tzouma, Victoria; Grepstad, Mari; Grimaccia, Federico; Kanavos, Panos
  • Comparing antibiotic prescribing between clinicians in UK primary care:an analysis in a cohort study of eight different measures of antibiotic prescribing. Van Staa, Tjeerd; Li, Yan; Gold, Natalie; Chadborn, Tim; Welfare, William; Palin, Victoria; Ashcroft, Darren M.; Bircher, Joanna picture_as_pdf
  • Therapeutic substitution post-patent expiry: the cases of ace inhibitors and proton pump inhibitors. Vandoros, Sotiris
  • The generics paradox revisited: empirical evidence from regulated markets. Vandoros, Sotiris; Kanavos, Panos
  • Reforms in the Greek pharmaceutical market during the financial crisis. Vandoros, Sotiris; Stargardt, Tom
  • Does adoption of pharmaceutical innovation respond to changes in the regulatory environment? Varol, Nebibe; Costa-Font, Joan; McGuire, Alistair
  • Benefit-risk assessment of cladribine using multi-criteria decision analysis (MCDA) for patients with relapsing-remitting multiple sclerosis. Vermersch, Patrick; Martinelli, Vittorio; Pfleger, Claudia; Rieckmann, Peter; Alonso-Magdalena, Lucia; Galazka, Andrew; Dangond, Fernando; Phillips, Lawrence D. picture_as_pdf
  • Expedited approvals and adverse drug reactions in women. Viehbeck, Constance picture_as_pdf
  • Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis:HTA evidence from seven OECD countries. Visintin, Erica; Tinelli, Michela; Kanavos, Panos
  • Price changes and within-class competition of cancer drugs in the USA and Europe:a comparative analysis. (2022) Vokinger, Kerstin N.; Hwang, Thomas J.; Carl, David L.; Laube, Yannic; Ludwig, Wolf Dieter; Naci, Huseyin; Kesselheim, Aaron S.
  • Negotiating drug prices in the US - lessons from Europe. Vokinger, Kerstin N.; Naci, Huseyin picture_as_pdf
  • Investments in research and development for supplemental drug indications:implications for drug price negotiations. (2023) Vokinger, Kerstin N.; Perényi, Gellért; Wouters, Olivier J. picture_as_pdf
  • Decision making under uncertainty:comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Vreman, Rick A.; Naci, Huseyin; Goettsch, Wim G.; Mantel-Teeuwisse, Aukje K.; Schneeweiss, Sebastian G.; Leufkens, Hubert G.M.; Kesselheim, Aaron S. picture_as_pdf
  • The US Food and Drug Administration’s expedited approval programs: addressing premarket flexibility with enhanced postmarket evidence generation. Wallach, Joshua D.; Ross, Joseph S.; Naci, Huseyin
  • Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018. (2022) Wouters, Olivier J.; Berenbrok, Lucas A.; He, Meiqi; Li, Yihan; Hernandez, Inmaculada picture_as_pdf
  • Product hopping in the drug industry — lessons from Albuterol. (2022) Wouters, Olivier J.; Feldman, William B.; Tu, S. Sean picture_as_pdf
  • Comparing generic drug markets in Europe and the United States:prices, volumes, and spending. Wouters, Olivier J.; Kanavos, Panos; McKee, Martin
  • Research and development costs of new drugs:in reply. Wouters, Olivier J.; McKee, Martin; Luyten, Jeroen
  • Early chronic kidney disease: diagnosis, management and models of care. Wouters, Olivier J.; O'Donoghue, Donal J.; Ritchie, James; Kanavos, Panos; Narva, Andrew S.
  • Cost-effectiveness of Midazolam versus Haloperidol versus Olanzapine for the management of acute agitation in the Accident and Emergency department. Yan, Vincent K.C.; Haendler, Miriam; Lau, Hayden; Li, Xue; Lao, Kim S.J.; Tsui, Sik Hon; Yap, Celene Y.L.; Knapp, Martin; Chan, Esther W. picture_as_pdf
  • Medical cannabis for severe treatment resistant epilepsy in children:a case-series of 10 patients. Zafar, Rayyan; Schlag, Anne; Phillips, Lawrence; Nutt, David J. picture_as_pdf
  • HPR253 Drug development and launch timeline analysis across 6 high-income countries:from pivotal trial to HTA. Zaitceva, V; Tan, I; Mills, M.; Kanavos, P.
  • Strength of evidence supporting cancer drug approvals in China, 2017-2021. Zhang, Yichen; Chen, Dingyi; Fu, Mengyuan; Shi, Luwen; Naci, Huseyin; Wagner, Anita Katharina; Ross, Joseph S.; Guan, Xiaodong
  • Overall survival benefits of cancer drugs approved in China from 2005 to 2020. (2022) Zhang, Yichen; Naci, Huseyin; Wagner, Anita K.; Xu, Ziyue; Yang, Yu; Zhu, Jun; Ji, Jiafu; Shi, Luwen; Guan, Xiaodong picture_as_pdf
  • Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021. Zhou, Yue; Naci, Huseyin; Chen, Dingyi; Bai, Lin; Shi, Luwen; Guan, Xiaodong; Wagner, Anita Katharina picture_as_pdf
  • HPR240 A rapid review of key challenges and success factors in implementing managed entry agreements for pharmaceuticals:lessons for Greece. Zisis, K.; Karampli, E.; Nomikos, N.; Agorastos, I; Naoum, P.; Tsiantou, V; Kyriopoulos, I; Pavi, E.
    • Book
  • Pharmaceutical pricing and reimbursement in Europe. Kanavos, Panos; Gemmill, Marin
    • Chapter
  • Afterword. Le Grand, Julian
  • Measuring value: pharmacoeconomics theory and practice. Towse, A; Drummond, Michael; Sorenson, Corinna
    • Conference or Workshop Item
  • Economic modelling of mindfulness meditation for people with mental health problems. Park, A-La; McDaid, David
    • Report
  • RWE in Europe Paper IV: Engaging pharma in the RWE Roadmap. Gill, Jennifer; Kanavos, Panos; d'Angela, Daniela; Berger, Karin; Dank, Magdolna; Duncombe, Robert; Fink-Wagner, Antje; Hutton, John; Kossler, Ingrid; Podrazilova, Katerina; Thomas, Michael
  • Measuring value: pharmacoeconomics in theory and practice. Towse, Adrian; Drummond, Michael; Sorenson, Corinna
    • Thesis
  • Pirates and property:the moralities of branded and generic medicines. Keeyaa, Chaurey picture_as_pdf
    • Online resource
  • Book review: The bitterest pills: the troubling story of antipsychotic drugs by Joanna Moncrieff. Brown, Sally
  • The digital future beyond the pill. Cornford, Tony
  • Parallel trade in medicinal drugs is putting the welfare of EU patients at risk. Costa-i-Font, Joan
  • The war over drugs: what’s at stake? Coulter, Steve
  • $1 million for a drug used once. Dickson, Jane
  • Enduring and emerging challenges of informed consent. Dickson, Jane
  • Personalized medicine: a podcast. Dickson, Jane
  • Stratified medicine in 2015 – Leeds Christmas lecture. Dickson, Jane
  • Vocal biomarkers: diagnostics through human voice. Dickson, Jane
  • Warfarin history timeline. Dickson, Jane
  • A decision support tool for warfarin prescribing. Dickson, Jane
  • Rhetoric vs reality: contraception in India and the DMPA debate. Hamilton, Zoe; Munger, Anne
  • Accelerating access to new drugs in Japan. Hibberd, Ralph
  • Brexit and the falsified medicines directive. Hibberd, Ralph
  • Combating falsified medicines in Africa through digital artefacts. Hibberd, Ralph
  • Hub and spoke dispensing: privacy and sociotechnical rigidity. Hibberd, Ralph
  • Hub and spoke dispensing: safety and sociotechnical pliability. Hibberd, Ralph
  • ‘the little liar’ – patient information about medicines. Lichtner, Valentina
  • Using international human rights law to guarantee the right to health: a Brazilian experience. Morais de Oliveira, Iago
  • Learning from India? A new approach to secondary pharmaceutical patents. Shadlen, Kenneth C. picture_as_pdf
  • Balancing innovation and access: India’s pharmaceutical patent laws. Shadlen, Kenneth C.; Sampat, Bhaven N.; Amin, Tahir M. picture_as_pdf
  • Long read review: drug dealer, MD: how doctors were duped, patients got hooked and why it’s so hard to stop by Anna Lembke. Williams, Thomas Christie
    • Working paper
  • Trade agreements, patents, and drug prices: continuing the debate. Kapczynski, Amy; Sampat, Bhaven N.; Shadlen, Kenneth C.
    • ['eprint_typename_blog_post' not defined]
  • Book review:the politics of weight: feminist dichotomies of power in dieting by Amelia Morris. Dean, Megan picture_as_pdf
  • The size of the US pharmaceutical market means that the US Food and Drug Administration has a disproportionately large global influence. Forrest, Robin picture_as_pdf
  • Biotechnology: why is Europe lagging behind the U.S.? Owen, Geoffrey picture_as_pdf
  • Drug patenting in India:looking back and looking forward. Shadlen, Kenneth C.; Sampat, Bhaven N. picture_as_pdf